Antibe Therapeutics Inc. Sustainability Profile
Antibe Therapeutics Inc., a pioneering biopharmaceutical company headquartered in Canada, focuses on developing innovative therapies for pain management and inflammation. Founded in 2010, Antibe has made significant strides in the industry, particularly with its lead product, ATB-346, which aims to provide safer alternatives to traditional non-steroidal anti-inflammatory drugs (NSAIDs). With a commitment to enhancing patient outcomes, Antibe's unique approach combines its proprietary hydrogen sulfide (H2S) technology with established drug compounds, setting it apart in the competitive landscape. The company has garnered attention for its promising clinical results and strategic partnerships, positioning itself as a key player in the pain management sector. As Antibe continues to advance its pipeline, it remains dedicated to addressing unmet medical needs and improving the quality of life for patients worldwide.
DitchCarbon Score
How does Antibe Therapeutics Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Antibe Therapeutics Inc.'s score of 59 is higher than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Antibe Therapeutics Inc., headquartered in Canada, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company is a current subsidiary of Sun Pharmaceutical Industries Limited, which may influence its climate commitments and emissions reporting. As of now, Antibe Therapeutics has not established any documented reduction targets or climate pledges. The absence of specific initiatives or targets suggests that the company may be in the early stages of developing its climate strategy or may rely on the broader commitments of its parent company. Given the lack of direct emissions data, it is essential to consider the context of the pharmaceutical industry, which is increasingly focusing on sustainability and carbon reduction. Companies within this sector are often encouraged to adopt science-based targets and engage in initiatives that align with global climate goals. In summary, while Antibe Therapeutics Inc. does not currently report emissions or specific climate commitments, its affiliation with Sun Pharmaceutical Industries Limited may provide a framework for future sustainability efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 77,616,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 377,728,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | 000,000,000 | 000,000,000 |
How Carbon Intensive is Antibe Therapeutics Inc.'s Industry?
How Carbon Intensive is Antibe Therapeutics Inc.'s Location?
Antibe Therapeutics Inc.'s Scope 3 Categories Breakdown
Antibe Therapeutics Inc.'s Scope 3 emissions, which increased by 6% last year and increased by approximately 6% since 2023, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 51% of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 62% of Scope 3 emissions.
Top Scope 3 Categories
Antibe Therapeutics Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Antibe Therapeutics Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
